

Women undergoing chemotherapy plus gonadotrophin-releasing hormone (GnRH) analogues compared with control to protect ovarian function

ACTRN12609001059257

Status	RECRUITING
Phase	Phase 2
Sponsor	Ass. Prof. Dr. Eman Elgindy
Enrollment	100 participants

Plain Language Summary

This study is looking at whether a hormone treatment given alongside chemotherapy can protect the ovaries of young women with cancer from being damaged by the chemotherapy drugs. Losing ovarian function from cancer treatment can cause early menopause and infertility. Researchers hope that giving a hormone called a GnRH analogue at the same time as chemotherapy might shield the ovaries during treatment.

You may be eligible if:

- You are a woman between 18 and 40 years old
- You have been diagnosed with cancer and need chemotherapy that includes a drug called cyclophosphamide
- You have both ovaries
- You do not have ovarian cysts larger than 40mm

You may NOT be eligible if:

- You have advanced or metastatic (spread) cancer
- Your cancer involves the ovaries, uterus, or fallopian tubes
- You have previously had chemotherapy or pelvic radiation
- You are currently on hormone therapy, biologic therapy, or corticosteroids
- You are pregnant or breastfeeding

Talk to your doctor about whether this trial might be right for you.

Key Eligibility Criteria

Inclusion (1)

- Women between 18 and 40 years old receiving cyclophosphamide-based chemotherapy for treatment of cancer with presence of both ovaries and absence of ovarian tumours or cysts over 40 mm in diameter demonstrated by transvaginal ultrasound

Exclusion (1)

- Advanced stage disease or evidence of metastases; Cancer of the ovaries, uterus, or fallopian tubes; Women who previously received chemotherapy or abdominal/pelvic radiation or are planned to receive abdomino-pelvic radiation; Patients taking hormone therapy biologic therapy or corticosteroids; Women who are pregnant or nursing.

Locations (2 total)

Zagazig (School of Medicine, Zagazig University), Egypt
Cairo (National Cancer Institute, Cairo University), Egypt

<https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=ACTRN12609001059257>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at anzctr.org.au. Generated by ClinicalTrialsFinder.org.